☆ 4.7 Article

Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer

EUROPEAN JOURNAL OF CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status

Nanae Horisawa et al.

Summary: The study retrospectively reviewed data from nearly 5000 primary breast cancer patients to determine the frequency of HER2-low and compare the prognosis of HER2-low patients with HER2-negative patients. The research found that HER2-low patients did not have significantly different prognosis than HER2-0 patients. Tailoring therapies for HER2-low early breast cancer patients based on hormone receptor status may be considered.

BREAST CANCER (2022)

Add to Collection

Article Oncology

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

Aileen Fernandez et al.

Summary: The current standard ERBB2 IHC assay may not be suitable for selecting patients with low ERBB2 positivity for treatment with T-DXd, as the accuracy of scoring for ERBB2 INC in the low range (0 and 1+) was poor in this study, raising the risk of misassigning patients for treatment with T-DXd.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China

Yiqun Li et al.

Summary: The study found that HER2-low breast cancer presents distinct clinical features and survival outcomes compared to HER2-negative breast cancer, particularly in the HR-positive subgroup. This type of breast cancer may have a more complex molecular landscape, and further research on more precise diagnostic algorithms could lead to new therapeutic targets.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis

Ryan Shea Ying Cong Tan et al.

Summary: This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC). The results showed that HER2-low BC had a superior prognosis compared to HER2-zero BC in the non-metastatic setting, though the absolute differences were modest and driven by HER2 IHC 1+ BC. Further investigation is needed for the ERBB2 CNV status in HER2-negative BC.

BMC MEDICINE (2022)

Add to Collection

Meeting Abstract Oncology

Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Veronique Dieras et al.

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Evolution of low HER2 expression between early and advanced-stage breast cancer

Paolo Tarantino et al.

Summary: This study reviewed data from HER2-negative breast cancer patients and evaluated the changes in HER2 expression during disease progression. The results showed significant discordance in HER2 expression between the primary tumor and the advanced biopsy samples, and HER2-low expression did not have prognostic significance.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, Research & Experimental

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Myrto Moutafi et al.

Summary: The efficacy of the antibody drug conjugate Trastuzumab deruxtecan (T-DXd) in HER2 low breast cancer patients suggests the need for revision of the conventional HER2 assays. In this study, an optimized dynamic range for unamplified HER2 detection in breast cancer was determined and a quantitative assay to stratify HER2 expression in unamplified cases was designed. The application of this assay to a large number of breast cancer cases demonstrated its potential for selecting optimal patients for T-DXd treatment.

LABORATORY INVESTIGATION (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society

Hye Sung Won et al.

Summary: HER2-low breast cancer and HER2-IHC 0 breast cancer have different clinicopathological characteristics and survival outcomes. HER2-low breast cancer is more common in hormone receptor-positive breast cancer but is associated with a high lymph node ratio and positive lymphatic invasion in triple-negative breast cancer. HER2-low breast cancer shows significantly better breast cancer-specific survival compared to HER2-IHC 0 breast cancer. These findings suggest that the biology and clinical impact of low HER2 expression may vary according to the hormone receptor status.

BREAST CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Raz Mutai et al.

Summary: This study compared disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor positive, early-stage breast cancer, finding significantly favorable outcomes of HER2-low expression compared to HER2-0 in women with high genomic risk.

BREAST (2021)

Add to Collection

Article Pharmacology & Pharmacy

Disitamab Vedotin: First Approval

Emma D. Deeks

Summary: Disitamab vedotin (Aidixi(R)) is an antibody-drug conjugate developed for the treatment of solid tumors, with its first Biologics License Application (BLA) approval obtained in China for HER2-overexpressing gastric cancer patients. It is also being studied globally for other solid tumors, including urothelial cancer in China and the USA, as well as biliary tract cancer, non-small cell lung cancer, HER2-positive, and HER2-low expressing breast cancer in China.

DRUGS (2021)

Add to Collection

Article Oncology

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini et al.

Summary: Novel antibody-drug conjugates targeting HER2 have shown high activity in HER2-negative breast cancer with low HER2 expression, but the clinical and molecular characteristics of HER2-low breast cancer remain unclear. This study reveals that HER2-low is more common in HR-positive disease than in TNBC, and emphasizes the significant biological heterogeneity of HER2-low BC, highlighting the importance of reproducible and sensitive assays for measuring low HER2 expression.

NPJ BREAST CANCER (2021)

Add to Collection

Article Oncology

HER2-low-positive breast cancer from four neoadjuvant clinical trials – Authors' reply

Carsten Denkert et al.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers

William Jacot et al.

Summary: The study evaluated HER2 expression and prognostic value in 296 patients with non-metastatic triple-negative breast cancer (TNBC). It was found that HER2 1+/2+ expression was associated with lower histological grade and molecular apocrine profile, with a subgroup of patients having worse long-term prognosis. The rare HER2 2+ TNBC subgroup showed worse relapse-free survival, emphasizing the need for dedicated evaluation for this group.

CANCERS (2021)

Add to Collection

Article Oncology

Evolution of HER2-low expression from primary to recurrent breast cancer

Federica Miglietta et al.

Summary: This study revealed that HER2-low expression is common in both primary and recurrent samples of HER2-negative breast cancer patients, and that HER2 expression is highly unstable during disease progression. Relapse biopsy from patients with primary HER2-negative tumors may present new therapeutic opportunities for a significant proportion of patients.

NPJ BREAST CANCER (2021)

Add to Collection

Article Oncology

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

Luciana de Moura Leite et al.

Summary: Our study does not support HER2-low as a biologically distinct subtype of breast cancer, showing no prognostic value on survival outcomes and no predictive effect for pathological complete response after conventional neoadjuvant chemotherapy.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Oncology

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Elisa Agostinetto et al.

Summary: The study characterized PAM50 intrinsic subtypes within HER2-low breast cancer and investigated the prognostic impact of HER2-low status on survival outcomes. The distribution of HER2-enriched tumors was higher in the HER2-low/HR- group compared to the HER2-low/HR+ group. However, there were no significant differences in survival outcomes between HER2-low subtypes and each non-HER2-low subtype when paired by HR status.

CANCERS (2021)

Add to Collection

Article Oncology

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+

Louis Fehrenbacher et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

R. K. Murthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Oncology

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Pathology

Distinguishing Score 0 From Score 1+in HER2 Immunohistochemistry-Negative Breast Cancer Clinical and Pathobiological Relevance

Kathleen Lambein et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Jose Baselga et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Oncology

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Edith A. Perez et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-025EFcomparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

M. Schmidt et al.

ANNALS OF ONCOLOGY (2009)

Add to Collection

Editorial Material Oncology

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

Richard M. Simon et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)

Add to Collection

Article Oncology

The humoral immune system has a key prognostic impact in node-negative breast cancer

Marcus Schmidt et al.

CANCER RESEARCH (2008)

Add to Collection

Letter Medicine, General & Internal

HER2 status and benefit from adjuvant trastuzumab in breast cancer

Soonmyung Paik et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

Charles E. Geyer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Oncology

REporting recommendations for tumour MARKer prognostic studies (REMARK)

LM McShane et al.

EUROPEAN JOURNAL OF CANCER (2005)

Add to Collection

Article Medicine, General & Internal

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

DJ Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.